Results 1 to 10 of about 5,625 (178)

Anti-inflammatory effects of tiotropium in COPD: a randomised double-blind trial [PDF]

ERJ Open Research
Background COPD is a major global health issue characterised by respiratory symptoms and exacerbations, significantly impacting mortality and quality of life.
Lisa H. van Smoorenburg, Tatiana Karp, Benedikt Ditz, Wouter H. van Geffen, Victor Guryev, Ali Almusa, Loes Kistemaker, Reinoud Gosens, Maarten van den Berge, Huib A.M. Kerstjens   +9 more
doaj   +2 more sources

Clinical predictors of treatment response to tiotropium add-on therapy in adult asthmatic patients: From multicenter real-world cohort data in Korea

World Allergy Organization Journal, 2022
Background: Tiotropium, a long-acting muscarinic antagonist, is recommended for add-on therapy to inhaled corticosteroids (ICS)-long-acting beta 2 agonists (LABA) for severe asthma.
Ji-Su Shim, MD, PhD, Juhae Jin, MA, Sae-Hoon Kim, MD, PhD, Taehoon Lee, MD, PhD, An-Soo Jang, MD, PhD, Chan Sun Park, MD, PhD, Jae-Woo Jung, MD, PhD, Jae-Woo Kwon, MD, PhD, Ji-Yong Moon, MD, PhD, Min-Suk Yang, MD, PhD, Jaechun Lee, MD, PhD, Jeong-Hee Choi, MD, PhD, Yoo Seob Shin, MD, PhD, Hee-Kyoo Kim, MD, PhD, Sujeong Kim, MD, PhD, Joo-Hee Kim, MD, PhD, Sang-Heon Cho, MD, PhD, Young-Hee Nam, MD, PhD, Sang-Hoon Kim, MD, PhD, So Young Park, MD, PhD, Gyu Young Hur, MD, PhD, Sang-Ha Kim, MD, PhD, Hye-Kyung Park, MD, PhD, Hyun Jung Jin, MD, PhD, Jae-Hyun Lee, MD, PhD, Jung-Won Park, MD, PhD, Ho Joo Yoon, MD, PhD, Byoung Whui Choi, MD, PhD, Young-Joo Cho, MD, PhD, Min-Hye Kim, MD, PhD, Tae-Bum Kim, MD, PhD   +30 more
doaj   +1 more source

Cost-effectiveness of the fixed-dose combination tiotropium/olodaterol versus tiotropium monotherapy or a fixed-dose combination of long-acting β2-agonist/inhaled corticosteroid for COPD in Finland, Sweden and the Netherlands: a model-based study

BMJ Open, 2021
Objectives Chronic obstructive pulmonary disease (COPD) guidelines advocate treatment with combinations of long-acting bronchodilators for patients with COPD who have persistent symptoms or continue to have exacerbations while using a single ...
Maureen Rutten-van Mölken, Martine Hoogendoorn, Isaac Corro Ramos, Stéphane Soulard, Jennifer Cook, Erkki Soini, Emma Paulsson   +6 more
doaj   +1 more source

Long-Term Once-Daily Tiotropium Respimat® Is Well Tolerated and Maintains Efficacy over 52 Weeks in Patients with Symptomatic Asthma in Japan: A Randomised, Placebo-Controlled Study. [PDF]

PLoS ONE, 2015
This study assessed the long-term safety and efficacy of tiotropium Respimat, a long-acting inhaled anticholinergic bronchodilator, in asthma, added on to inhaled corticosteroids (ICS) with or without long-acting β2-agonist (LABA).285 patients with ...
Ken Ohta, Masakazu Ichinose, Yuji Tohda, Michael Engel, Petra Moroni-Zentgraf, Satoko Kunimitsu, Wataru Sakamoto, Mitsuru Adachi   +7 more
doaj   +1 more source

Protective effects of tiotropium alone or combined with budesonide against cadmium inhalation induced acute neutrophilic pulmonary inflammation in rats. [PDF]

PLoS ONE, 2018
As a potent bronchodilator, the anti-inflammatory effects of tiotropium and its interaction with budesonide against cadmium-induced acute pulmonary inflammation were investigated.
Shiwei Zhao, Qi Yang, Zhixi Yu, You Lv, Jianming Zhi, Pascal Gustin, Wenhui Zhang   +6 more
doaj   +1 more source

Effect of tiotropium inhaler use on mortality in patients with tuberculous destroyed lung: based on linkage between hospital and nationwide health insurance claims data in South Korea

Respiratory Research, 2019
Background Although bronchodilator inhaler therapy can improve lung function in patients with tuberculous destroyed lung (TDL), its effect on mortality has not been studied.
Ho Cheol Kim, Tae Hoon Kim, Ye-Jee Kim, Chin Kook Rhee, Yeon-Mok Oh   +4 more
doaj   +1 more source

Effects of tiotropium on the risk of coronary heart disease in patients with COPD: a nationwide cohort study

Scientific Reports, 2022
Inhaled long-acting muscarinic antagonist (LAMA) is recommended for the treatment of chronic obstructive pulmonary disease (COPD). However, there is still concern that LAMA may cause cardiovascular adverse events in COPD patients.
Jiyoung Shin, Jin Hwa Lee
doaj   +1 more source

Real-world effectiveness of early intervention with fixed-dose tiotropium/olodaterol vs tiotropium in Japanese patients with COPD: a high-dimensional propensity score–matched cohort analysis

Respiratory Research, 2021
Background Escalation to triple therapy (long-acting muscarinic antagonist/β2-agonist, inhaled corticosteroid [ICS]) in chronic obstructive pulmonary disorder (COPD) is recommended for patients on LAMA/LABA combinations with frequent exacerbations and ...
Shigeo Muro, Masaru Suzuki, Shuhei Nakamura, Jocelyn Ruoyi Wang, Elizabeth M. Garry, Wataru Sakamoto, Sabrina de Souza   +6 more
doaj   +1 more source

Update on Long-Acting Anticholinergics in Children and Adolescents With Difficult and Severe Asthma

Frontiers in Pediatrics, 2022
Tiotropium bromide is the only long-acting muscarinic antagonist (LAMA) approved for treatment of patients aged ≥6 years old who have symptoms of uncontrolled asthma.
Francesca Santamaria, Carla Ziello, Paola Lorello, Cristina Bouchè, Melissa Borrelli   +4 more
doaj   +1 more source

Tiotropium in the add-on treatment of asthma in adults: clinical trial evidence and experience

Therapeutic Advances in Respiratory Disease, 2016
Asthma is a chronic inflammatory airway disease, and its treatment is frequently challenging despite detailed national and international guidelines. While basic anti-inflammatory therapy usually consists of inhaled corticosteroids in doses adapted to the
Christian Vogelberg
doaj   +1 more source